Senti Biosciences - SNTI Enterprise Value-to-Sales Ratio

Public company logo of Senti Biosciences, Inc. (SNTI)

The allogeneic platform of Senti Biosciences, Inc. (SNTI) reduces per-patient costs, which correlates with the firm's EV/Sales multiple valuation, currently standing at 332142.86. Business stability is based on unique gene circuits for the targeted destruction of tumors. The implementation of software robots for data analysis accelerates drug release. This chart demonstrates the company's market maturity through the prism of its operating revenues.

Senti Bio (SNTI): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Senti Biosciences (SNTI)

Fundamental valuation:Senti Bio (SNTI)
Core merchandise of sentibio.com

This indicator assesses the total enterprise value relative to generated revenue, accounting for net debt, to determine whether assets are overvalued or undervalued by the market. By analyzing the EV-to-revenue ratio, an investor can identify capital stagnation risks or the growth potential of Senti Biosciences, Inc. (SNTI), whose market capitalization is driven by the uniqueness of its developments in programmable gene circuits for precision oncology therapy.